Content about Prostate cancer

April 1, 2014

A derivative of vitamin A, known as retinoic acid, found abundantly in sweet potato and carrots, helps turn pre-cancer cells back to normal healthy breast cells, according to research published this month in the International Journal of Oncology.

PHILADELPHIA — A derivative of vitamin A, known as retinoic acid, found abundantly in sweet potato and carrots, helps turn pre-cancer cells back to normal healthy breast cells, according to research published this month in the International Journal of Oncology. The research could help explain why some clinical studies have been unable to see a benefit of vitamin A on cancer: the vitamin doesn’t appear to change the course of full-blown cancer, only pre-cancerous cells, and only works at a very narrow dose.

January 20, 2014

Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may decrease the risk of developing advanced prostate cancer, according to results presented here at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21.

SAN DIEGO — Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may decrease the risk of developing advanced prostate cancer, according to results presented here at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21.

January 13, 2014

Real Health Labs recently launched Prostate Complete Once Per Day, a pharmaceutical-grade supplement combination, the company stated.

SAN DIEGO — Real Health Labs recently launched Prostate Complete Once Per Day, a pharmaceutical-grade supplement combination, the company stated. 

In addition to zinc, selenium and vitamin E, Prostate Complete Once Per Day is formulated with a standardized saw palmetto extract, lycopene, a standardized curcumin extract, resveratrol and a pomegranate concentrate. 

December 3, 2013

The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

The FDA granted tentative approval to Roxane Labs' dutasteride capsules in the 0.5-mg strength. The drug is a generic version of GSK's Avodart, used to treat benign prostatic hyperplasia.

Tentative approval means that a drug meets the agency's conditions for approval, but can't receive final approval until Avodart loses its patent protection, which will occur in 2015.

 

November 26, 2013

German chemical and pharmaceutical giant Bayer plans to buy Norwegian drug maker Algeta for $2.4 billion, Algeta confirmed Tuesday.

OSLO, Norway — German chemical and pharmaceutical giant Bayer plans to buy Norwegian drug maker Algeta for $2.4 billion, Algeta confirmed Tuesday.

Responding to earlier media reports, the Norway-based maker of cancer drugs said Bayer would acquire it for 336 krone per share, equal to about $55.05. The company's share price increased to 349.40 krone, or $57.21 per share, in late-afternoon trading Tuesday on the Oslo Stock Exchange.

September 6, 2013

Safeway on Friday announced that its stores raised $10.3 million during the company's annual Prostate Cancer Awareness campaign.

PLEASANTON, Calif. — Safeway on Friday announced that its stores raised $10.3 million during the company's annual Prostate Cancer Awareness campaign.

For the 13th consecutive year, Safeway's entire chain of more than 1,600 stores dedicated a month to raising money and increasing awareness for the fight against prostate cancer, which currently affects more than two million American men and remains the second-leading cause of cancer death for men in the United States. 

August 26, 2013

Former Kinray owner Stewart Rahr has made a large donation to an organization looking for a cure for prostate cancer.

NEW YORK — Former Kinray owner Stewart Rahr has made a large donation to an organization looking for a cure for prostate cancer.

Saying the move "stunned the crowd," Rahr announced at a gathering at the Hamptons on New York's Long Island that he would donate $3 million to the Prostate Cancer Foundation, an initiative run by investor Michael Milken, who was host to the event.

Other attendees included David Koch, Eddie Trump, former New York Gov. David Patterson and others.

August 19, 2013

The limitations within a recent study linking omega-3 fish oil and increased prostate cancer risk ought to be taken in consideration, according to a commentary published in the August issue of Natural Medicine Journal.

WASHINGTON — The limitations within a recent study linking omega-3 fish oil and increased prostate cancer risk ought to be taken in consideration, according to a commentary published in the August issue of Natural Medicine Journal

July 12, 2013

A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center that claimed to confirm the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer drew a stark industry response from supplement trade associations.

SEATTLE — A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center released on Wednesday that claimed to confirm the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer drew a stark industry response from supplement trade associations.

June 17, 2013

Drug maker Johnson & Johnson plans to spend up to $1 billion to acquire a privately owned company developing a drug for prostate cancer.

NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson plans to spend up to $1 billion to acquire a privately owned company developing a drug for prostate cancer.

J&J said Monday it would acquire Aragon Pharmaceuticals for $650 million upfront plus up to $350 million in milestone payments, with the expectation that the deal will close in third quarter 2013.

May 31, 2013

Sam's Club will host free health screenings for men's health next month, the club retailer said.

BENTONVILLE, Ark. — Sam's Club will host free health screenings for men's health next month, the club retailer said.

Sam's Club said it would offer free screenings at all of its 565 stores with pharmacies on June 8 for Men's Health Month. The screenings include screenings for prostate cancer, as well as thyroid tests for women, blood pressure tests, body mass index and vision tests.

May 22, 2013

The Safeway Foundation and Stand Up To Cancer, a program of the Entertainment Industry Foundation, have teamed up to develop a print, radio and digital public service announcement featuring actress and SU2C Ambassador Marcia Cross. The PSA is designed to increase awareness for the fight against prostate cancer.

LOS ANGELES and NEW YORK — The Safeway Foundation and Stand Up To Cancer, a program of the Entertainment Industry Foundation, have teamed up to develop a print, radio and digital public service announcement featuring actress and SU2C Ambassador Marcia Cross. The PSA is designed to increase awareness for the fight against prostate cancer.

Prostate cancer is the second-leading cause of cancer death for men in the United States, and currently affects more than two million American men. One-in-six men will be diagnosed with prostate cancer in their lifetime.

May 15, 2013

A new treatment for late-stage prostate cancer has received approval from the Food and Drug Administration.

SILVER SPRING, Md. — A new treatment for late-stage prostate cancer has received approval from the Food and Drug Administration.

The FDA announced Wednesday the approval of Bayer's Xofigo (radian Ra 223 dichloride) for men with symptomatic, castration-resistant prostate cancer that has spread to the bones but not other organs, also known as metastasis. The drug is designed for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

May 15, 2013

Kimberly-Clark announced the launch of Depend Guards and Shields, two products specifically designed for men with light bladder leakage, along with tips and tools from former professional football star Tony Siragusa in a new program called Guard Your Manhood

DALLAS — Kimberly-Clark on Wednesday announced the launch of Depend Guards and Shields, two products specifically designed for men with light bladder leakage, along with tips and tools from former professional football star Tony Siragusa in a new program called Guard Your Manhood

January 9, 2013

Four-time NBA champion John Salley will be heading here next week to attend the ECRM Vitamin, Diet and Sports Nutrition conference in support of Natural Product Solutions.

SAN ANTONIO, Texas — Four-time NBA champion John Salley will be heading here next week to attend the ECRM Vitamin, Diet and Sports Nutrition conference in support of Natural Product Solutions. 

Salley is NPS' spokesman for VirMax, a line that consists of five supplement products that are formulated to benefit health levels of testosterone, a healthy prostate and other men’s health issues.

December 10, 2012

The Food and Drug Administration has approved a new use for a cancer drug made by Johnson & Johnson, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Johnson & Johnson, the agency said Monday.

The FDA announced the approval of Zytiga (abiraterone acetate), made by J&J subsidiary Janssen Biotech, for men with castration-resistant prostate cancer that has spread to other parts of the body, for use prior to receiving chemotherapy. The drug was already approved for castration-resistant prostate cancer in men who had already undergone chemotherapy treatment.

November 5, 2012

Natural Products Solutions recently announced the launch of VirMax T Testosterone. As part of that launch, DSN caught up with NPS president and CEO Marty Gallant to discuss men’s health supplements. 


Natural Products Solutions recently announced the launch of VirMax T Testosterone. As part of that launch, DSN caught up with NPS president and CEO Marty Gallant to discuss men’s health supplements. 


DSN: Men aren’t too proactive addressing their own health issues. How do you market to them?


October 17, 2012

In a randomized trial that included nearly 15,000 male physicians and started in 1997, long-term daily multivitamin use resulted in a modest, but statistically significant, reduction in cancer after more than a decade of treatment and follow-up, according to a study appearing in JAMA that was released Wednesday.

CHICAGO — In a randomized trial that included nearly 15,000 male physicians and started in 1997, long-term daily multivitamin use resulted in a modest, but statistically significant, reduction in cancer after more than a decade of treatment and follow-up, according to a study appearing in JAMA that was released Wednesday. The multivitamin used in the study was Pfizer's Centrum Silver. 

October 4, 2012

Membership-based retailer Sam's Club is offering free health screenings for women, the company said.

BENTONVILLE, Ark. — Membership-based retailer Sam's Club is offering free health screenings for women, the company said.

September 28, 2012

Drug maker OncoGenex Pharmaceuticals has started its third late-stage clinical trial of a drug for treating a type of lung cancer.

BOTHELL, Wash. — Drug maker OncoGenex Pharmaceuticals has started its third late-stage clinical trial of a drug for treating a type of lung cancer.

OncoGenex announced Friday the initiation of the phase-3 "ENSPIRIT" trial of custirsen in patients with nonsmall cell lung cancer that has spread to other parts of the body, also known as metastasis, and whose disease has progressed after initial treatment with chemotherapy has failed.

September 4, 2012

The Food and Drug Administration has approved a new drug made by Astellas Pharma U.S. and Medivation for treating prostate cancer, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Astellas Pharma U.S. and Medivation for treating prostate cancer, the agency said Friday.

The FDA announced the approval of Xtandi (enzalutamide) for castration-resistant prostate cancer that has spread or recurred despite medical or surgical therapy to minimize testosterone.

August 30, 2012

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

DALLAS — Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

August 15, 2012

The Food and Drug Administration has approved a drug for enlarged prostate made by generic drug maker Wockhardt, the company said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for enlarged prostate made by generic drug maker Wockhardt, the company said.

Wockhardt, based in Mumbai, India, announced the approval of alfuzosin hydrochloride extended-release tablets in the 10-mg strength, which is designed to treat enlarged prostate, also known as benign prostatic hyperplasia.

The drug is a generic version of Sanofi's Uroxatral. Various versions of the drug have sales of about $81.5 million, according to IMS Health.

August 13, 2012

A large new observational study published Friday found more evidence of an association between daily aspirin use and modestly lower cancer mortality, but suggested any reduction may be smaller than that observed in a recent analysis. The study appeared online in the Journal of the National Cancer Institute.

ATLANTA — A large new observational study published Friday found more evidence of an association between daily aspirin use and modestly lower cancer mortality, but suggested any reduction may be smaller than that observed in a recent analysis. The study appeared online in the Journal of the National Cancer Institute.

July 27, 2012

Men diagnosed with prostate cancer are less likely to die from the disease than from such preventable conditions as heart disease, according to a new study from Harvard School of Public Health.

BOSTON — Men diagnosed with prostate cancer are less likely to die from the disease than from such preventable conditions as heart disease, according to a new study from Harvard School of Public Health.